Which pharmaceutical product development innovation first introduced the concept of 'long-acting injectables' (LAIs) for the treatment of schizophrenia?

The healthcare industry has seen remarkable product development innovations that have revolutionized patient care and treatment outcomes. This poll tests your knowledge about a significant breakthrough in pharmaceutical product development that changed how medications are delivered to patients with chronic conditions. Understanding these innovations helps us appreciate the evolution of medical product design and its impact on patient adherence and quality of life.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Risperdal Consta (risperidone), launched in 2003 as the first atypical antipsychotic LAI
Haldol Decanoate (haloperidol), which was actually a conventional antipsychotic LAI introduced in the 1980s
Zyprexa Relprevv (olanzapine), which was the third atypical antipsychotic LAI to enter the market in 2009
Invega Sustenna (paliperidone palmitate), which was actually the second atypical antipsychotic LAI introduced in 2009